A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small
A phase 2 trial of Oleclumab, Durvalumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) is a phase 2 interventional study registered as NCT06606847 by AstraZeneca, with 30 participants enrolled, started 2024-09-24 and due to reach its primary completion in 2026-05-04. Interventions recorded: Oleclumab, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialOleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Shares Oleclumab, AstraZeneca, Non-small-cell lung cancer.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer.
- TrialNeoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca, Non-small-cell lung cancer.
- TrialA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Shares Oleclumab, AstraZeneca, Non-small-cell lung cancer.
- TrialCOLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
Shares Oleclumab, Durvalumab, AstraZeneca.
- TrialPhase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.